AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 6723769
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg cimetidine with water
Trial: 20211022
Drug: Pemetrexed (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed (500 mg/m2 on day 1 of a 21-day cycle) plus best supportive care (BSC)
Trial: 17923543
Drug: Intravitreal bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal bevacizumab (2.5 mg)
Trial: 9797791
Drug: Ritonavir (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritonavir (200 mg every 8 hours)
Trial: 9797791
Drug: Clarithromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin (500 mg every 12 hours)
Trial: 9797791
Drug: Ritonavir and
RxNorm normalized name: lopinavir and ritonavir
DrugBank: Lopinavir (DB01601)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ritonavir and clarithromycin in combination
Trial: 8044016
Drug: TCM‐WM therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCM‐WM therapy (oral administration and external treatment of TCM plus wet-compressing with antibiotics)
Trial: 8044016
Drug: WM therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WM therapy (Western medicine therapy including pain-killer, antibiotics, debridement and dressing change)
Trial: 1090718
Drug: Intraperitoneal cephaloridine
RxNorm normalized name: cephaloridine
DrugBank: Cefaloridine (DB09008)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal cephaloridine (25 mg/kg every 6 hr for 48 hr)
Trial: 1090718
Drug: Systemic injection
RxNorm normalized name: Vaginal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic injection of cephaloridine
Trial: 31208499
Drug: Early short-term
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early short-term upgrade therapy (ICS/LABA inhaled every morning for 7-10 days)
Trial: 27761000
Drug: T80/A5/H12.5 (telmisartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T80/A5/H12.5 (telmisartan 80 mg/amlodipine 5 mg plus hydrochlorothiazide 12.5 mg)
Trial: 27761000
Drug: T80/A5 (telmisartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T80/A5 (telmisartan 80 mg/amlodipine 5 mg)
Trial: 27005658
Drug: Resveratrol supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol supplementation (75 mg twice daily)
Trial: 20808251
Drug: Fentanyl (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (1 μg/kg bolus)
Trial: 20808251
Drug: Remifentanil (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil (0.5 μg/kg bolus)
Trial: 17295579
Drug: Multidimensional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidimensional treatment foster care (MTFC)
Trial: 10215753
Drug: Alniditan 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alniditan 2 mg
Trial: 10215753
Drug: Alniditan 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alniditan 4 mg
Trial: 6339289
Drug: Halometasone ointment
RxNorm normalized name: halometasone
DrugBank: Halometasone (DB13728)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Halometasone ointment (0.05%)
Trial: 6339289
Drug: Fluocortolone +
RxNorm normalized name: fluocortolone
DrugBank: Fluocortolone (DB08971)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluocortolone + fluocortolone caproate ointment (0.25% each)
Trial: 31696724
Drug: Fully Covered
RxNorm normalized name: Canker Cover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fully Covered Self-Expandable Biliary Metal Stents (FCSEBMS) placed for treatment of refractory bleed in 7 patients
Trial: 26255546
Drug: Coenzyme Q10
RxNorm normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coenzyme Q10 (200 mg/d)
Trial: 27169685
Drug: Alphacalcidol 1 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alphacalcidol 1 μg daily for 6 months
Trial: 27169685
Drug: Cholecalciferol 1 000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol 1 000 IU daily for 6 months
Trial: 23359516
Drug: Faldaprevir 120
RxNorm normalized name: Faldaprévir
DrugBank: Faldaprevir (DB11808)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Faldaprevir 120 mg QD with lead-in (LI)
Trial: 23359516
Drug: Faldaprevir 240
RxNorm normalized name: Faldaprévir
DrugBank: Faldaprevir (DB11808)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Faldaprevir 240 mg QD with lead-in (LI)
Trial: 23359516
Drug: Faldaprevir 240
RxNorm normalized name: Faldaprévir
DrugBank: Faldaprevir (DB11808)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Faldaprevir 240 mg QD
Trial: 23359516
Drug: Faldaprevir 240
RxNorm normalized name: Faldaprévir
DrugBank: Faldaprevir (DB11808)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Faldaprevir 240 mg QD in mRVR patients
Trial: 23359516
Drug: Faldaprevir 240
RxNorm normalized name: Faldaprévir
DrugBank: Faldaprevir (DB11808)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Faldaprevir 240 mg QD in GT-1a patients
Trial: 23359516
Drug: Faldaprevir 120
RxNorm normalized name: Faldaprévir
DrugBank: Faldaprevir (DB11808)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Faldaprevir 120 mg QD/LI
Trial: 23359516
Drug: Faldaprevir 240
RxNorm normalized name: Faldaprévir
DrugBank: Faldaprevir (DB11808)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Faldaprevir 240 mg QD/LI
Trial: 19843000
Drug: Sildenafil citrate
RxNorm normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sildenafil citrate (20 mg three times daily, increased to 40 mg and 80 mg tid)
Trial: 19843000
Drug: Sildenafil citrate
RxNorm normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sildenafil citrate (20 mg, 40 mg, and 80 mg tid)
Trial: 12539684
Drug: Millimeter wave
RxNorm normalized name: ELECTRODE GEL,H-WAVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Millimeter wave treatment (7.1 mm, 43 GHz, 10 mW/cm2)
Trial: 12539684
Drug: Millimeter wave
RxNorm normalized name: ELECTRODE GEL,H-WAVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Millimeter wave treatment
Trial: 12539684
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (soothing treatment)
Trial: 9018645
Drug: Low-dose oxytocin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose oxytocin (2 mU/min, increased by 2 mU/min at 30-minute intervals) started immediately after PGE2 placement
Trial: 9018645
Drug: Low-dose oxytocin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose oxytocin (2 mU/min, increased by 2 mU/min at 30-minute intervals) started six hours after PGE2 placement
Trial: 25599319
Drug: Platelet Gel
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet Gel Supernatant (PGS) plus supportive medical treatment
Trial: 25599319
Drug: Supportive medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive medical treatment alone
Trial: 19342442
Drug: No supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No supplements (Control group)
Trial: 16650363
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg atorvastatin for 8 weeks
Trial: 11714895
Drug: Morphine sulfate
RxNorm normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine sulfate 5 mg/70 kg, i.v. at various infusion rates (2 min bolus, 15 min, 60 min)
Trial: 11714895
Drug: Morphine sulfate
RxNorm normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine sulfate 10 mg/70 kg, i.v. at various infusion rates (2 min bolus, 15 min, 60 min)
Trial: 11714895
Drug: Placebo 0
RxNorm normalized name: Norethindrone;Placebo 0.35 MG; NA Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 0 mg/70 kg, i.v. at various infusion rates (2 min bolus, 15 min, 60 min)
Trial: 11714895
Drug: Faster infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Faster infusion rates of morphine
Trial: 11714895
Drug: Morphine (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (both doses)
Trial: 9137028
Drug: 6-hour heparin
RxNorm normalized name: Heparine
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6-hour heparin flushing interval
Trial: 9137028
Drug: 8-hour heparin
RxNorm normalized name: Heparine
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8-hour heparin flushing interval
Trial: 9137028
Drug: 4-hour heparin
RxNorm normalized name: Heparine
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-hour heparin flushing interval
Trial: 8181019
Drug: Angiotensin converting
RxNorm normalized name: Angiotensin converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin converting enzyme inhibitors (ACE-I)
Trial: 8181019
Drug: Aldosterone antagonists
RxNorm normalized name: Aldosterone antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aldosterone antagonists or alternative RAAS blockers (renin inhibitors or angiotensin II receptor blocking agents)
Trial: 2142116
Drug: Intramuscular etofenamate
RxNorm normalized name: etofenamate
DrugBank: Etofenamate (DB08984)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular etofenamate
Trial: 2142116
Drug: Intramuscular diclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular diclofenac sodium
Trial: 580214
Drug: commercial drug
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: commercial drug mixture (acetylsalicylic acid 200 mg; phenacetin 200 mg; codeine phosphor. 10 mg; caffeine anhydr. 50 mg; phenobarbital 25 mg)
Trial: 29380610
Drug: Ultrasound enamel
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound enamel preparation
Trial: 31102045
Drug: Conventional diamond
RxNorm normalized name: diamond
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional diamond bur preparation
Trial: 21665136
Drug: Psychosocial support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychosocial support therapy (PST) control
Trial: 19803365
Drug: Cytoflavine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytoflavine (10 mL per 24 hours, for 5 days)
Trial: 19803365
Drug: Standard antituberculosis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antituberculosis therapy (placebo control)
Trial: 11315893
Drug: Topical GTN
RxNorm normalized name: GTN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical GTN (10 mg)
Trial: 21067823
Drug: Topical saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical saline
Trial: 11315893
Drug: Topical ISDN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ISDN (10 mg)
Trial: 11315893
Drug: Topical GTN
RxNorm normalized name: GTN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical GTN
Trial: 11315893
Drug: Topical ISDN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ISDN
Trial: 3568581
Drug: Beta-blockade (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blockade (2 X 80 mg oral propranolol)
Trial: 27108821
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (2.5g intravenous, 5min before tourniquet release)
Trial: 24015935
Drug: Magnesium supplementation
RxNorm normalized name: Magnesium
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium supplementation (350 mg Mg d(‐1), 4 weeks)
Trial: 24015935
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (500 mg maltodextrin d(‐1), 4 weeks)
Trial: 23541623
Drug: 5 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 μg of EV71 antigen with 150 μg of adjuvant (Group A05)
Trial: 23541623
Drug: 10 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 μg of EV71 antigen with 300 μg of adjuvant (Group B10)
Trial: 20881846
Drug: quetiapine XR
RxNorm normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: quetiapine XR (50-300 mg/day)
Trial: 8668894
Drug: High-dose i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose i.v. methylprednisolone
Trial: 8668894
Drug: Oral steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral steroids (1 mg per kilogram of body weight per day)
Trial: 2067345
Drug: Prodigiosan plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prodigiosan plus ibuprofen
Trial: 6409456
Drug: Cholinergic antagonist,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholinergic antagonist, pirenzepine
Trial: 29985775
Drug: Protein-based supplement
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein-based supplement containing 1546 mg of omega-3 polyunsaturated fatty acid (551 mg EPA and 551 mg DHA) twice daily (FO)
Trial: 29985775
Drug: Protein-based supplement
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein-based supplement containing 1546 mg of omega-3 polyunsaturated fatty acid (FO)
Trial: 19958042
Drug: Ondansetron (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (0.25 mg twice daily for 6 weeks, then 0.5 mg twice daily for 6 weeks)
Trial: 15385341
Drug: Esmolol plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol plus enoximone (initial bolus of 0.5 mg/kg followed by a continuous infusion of 2.5 microg x kg(‐1) x min(‐1))
Trial: 2670395
Drug: Adrenaline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenaline infusion at 0.5 microgram/min
Trial: 2670395
Drug: Adrenaline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenaline infusion at 3 microgram/min
Trial: 2670395
Drug: Noradrenaline infusion
RxNorm normalized name: noradrenaline hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noradrenaline infusion at 0.5 microgram/min
Trial: 2670395
Drug: Noradrenaline infusion
RxNorm normalized name: noradrenaline hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noradrenaline infusion at 3 microgram/min
Trial: 2670395
Drug: Adrenaline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenaline infusion at 6 microgram/min
Trial: 2670395
Drug: Noradrenaline infusion
RxNorm normalized name: noradrenaline hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noradrenaline infusion at 6 microgram/min
Trial: 824068
Drug: Inhaled BRL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled BRL 10833, dosage: 40 mg
Trial: 23439063
Drug: PC‐DC injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PC‐DC injections
Trial: 17869451
Drug: C/F chemotherapy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C/F chemotherapy, cisplatin dose >or=200 mg/m(2), Stage I‐II disease, negative pelvic lymph nodes
Trial: 15319332
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg of [(14)C]tesaglitazar (intravenous)
Trial: 15319332
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg of nonlabeled tesaglitazar (oral)
Trial: 24102348
Drug: Oral liarozole
RxNorm normalized name: letrozole Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral liarozole 75 mg
Trial: 24102348
Drug: Oral liarozole
RxNorm normalized name: letrozole Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral liarozole 150 mg
Trial: 24102348
Drug: Oral liarozole
RxNorm normalized name: letrozole Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral liarozole (both doses)
Trial: 22609619
Drug: Acute dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute dose of levodopa
Trial: 18078614
Drug: Combination DMARD
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination DMARD therapy (sulfasalazine, methotrexate, hydroxychloroquine)
Trial: 18078614
Drug: Single DMARD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single DMARD therapy
Trial: 10522283
Drug: Sequential group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential group (S)
Trial: 8770718
Drug: Adequate antidepressant
RxNorm normalized name: Adequan
DrugBank: Polysulfated glycosaminoglycan (DB11538)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adequate antidepressant treatment (dosage not specified)
Trial: 8770718
Drug: Low-intensity antidepressant
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity antidepressant treatment (dosage not specified)
Trial: 8770718
Drug: Low-intensity treatment
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity treatment
Trial: 8770718
Drug: Higher-intensity treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher-intensity treatment
Trial: 7006619
Drug: Propranolol, given
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol, given four times daily
Trial: 7006619
Drug: Penbutolol, given
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Penbutolol, given once daily
Trial: 29860661
Drug: 1500 mg
RxNorm normalized name: inulin 1500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500 mg vitamin C daily 2 days after RAIT
Trial: 29860661
Drug: 1500 mg
RxNorm normalized name: inulin 1500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500 mg vitamin C daily 2 days before to 2 days after RAIT
Trial: 29860661
Drug: 1500 mg
RxNorm normalized name: inulin 1500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500 mg vitamin C daily 2 days before RAIT
Trial: 17192497
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg intranasal ketorolac
Trial: 17192497
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg intranasal ketorolac
Trial: 17192497
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg intramuscular ketorolac
Trial: 8988064
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg intramuscular ketorolac
Trial: 17192497
Drug: Intranasal ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal ketorolac (both doses)
Trial: 15292384
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (MeCCNU, vincristine, 5-fluorouracil)
Trial: 15292384
Drug: Adjuvant immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant immunotherapy (bacillus Calmette‐Guérin)
Trial: 11800507
Drug: Zolpidem 10
RxNorm normalized name: zolpidem 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem 10 mg 5 nights/week
Trial: 10526810
Drug: Propofol (1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (1, 2, 3, 4, 5, or 6 micrograms/ml) and Sufentanil (0.1, 0.2, 0.3, 0.5, or 1.0 ng/ml) target blood concentrations
Trial: 2264951
Drug: Baclofen 40
RxNorm normalized name: baclofen 40,000 MCG per 20 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baclofen 40 mg/day
Trial: 2264951
Drug: Baclofen 80
RxNorm normalized name: Baclofen
DrugBank: Baclofen (DB00181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Baclofen 80 mg/day
Trial: 375802
Drug: Cefazolin, 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefazolin, 1 gm intramuscularly preoperatively, then 0.5 gm every six hours for four doses
Trial: 21385856
Drug: oral 6‐mercaptopurine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral 6‐mercaptopurine and intramuscular methotrexate (arm 1)
Trial: 21385856
Drug: no further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no further therapy (arm 4)
Trial: 16472976
Drug: Branched-chain-enriched amino
RxNorm normalized name: Machilus thunbergii branch extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Branched-chain-enriched amino acid mixture infused at 82 mg x h(‐1) x kg(‐1) for 3 hours
Trial: 16472976
Drug: Balanced amino
RxNorm normalized name: silk amino acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balanced amino acid infusion
Trial: 10809242
Drug: 2.0 L
RxNorm normalized name: NUTREN 2.0 LIQUID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 L dialysate fill volume
Trial: 10809242
Drug: 2.5 L
RxNorm normalized name: ALCOHOL 1.875 L in 2.5 L TOPICAL LIQUID [EXIHUAN Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 L dialysate fill volume
Trial: 10809242
Drug: 3.0 L
RxNorm normalized name: The full generic name for the drug abbreviation '3.0 L' is not clear from the information provided. The abbreviation '3.0 L' could refer to various drug formulations or dosages, and without more context, it is not possible to determine the specific full generic name. The best response would be to indicate that the full generic name cannot be determined from the given information.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.0 L dialysate fill volume
Trial: 8752629
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg of dexamethasone
Trial: 6340970
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg tiaprofenic acid daily for 3 months